Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

View All Documentation

E7906

Sigma-Aldrich

Esomeprazole magnesium hydrate

≥98% (HPLC)

Synonyma:

(S)-Omeprazole magnesium hydrate, (T-4)-Bis[6-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl-κO]-1H-benzimidazolato-κN3]-Magnesium hydrate, Nexium hydrate

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(1)

About This Item

Empirický vzorec (Hillův zápis):
C34H36MgN6O6S2 · xH2O
Číslo CAS:
668985-31-7
Molekulová hmotnost:
713.12 (anhydrous basis)
UNSPSC Code:
12352200
PubChem Substance ID:
329799074
NACRES:
NA.77

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -128 to -146°, c = 0.5 in methanol

color

white to off-white

solubility

DMSO: ≥5 mg/mL

originator

AstraZeneca

storage temp.

2-8°C

SMILES string

O.COc1ccc2n([Mg]n3c(nc4cc(OC)ccc34)S(=O)Cc5ncc(C)c(OC)c5C)c(nc2c1)S(=O)Cc6ncc(C)c(OC)c6C

InChI

1S/2C17H18N3O3S.Mg.H2O/c2*1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;;/h2*5-8H,9H2,1-4H3;;1H2/q2*-1;+2;/t2*24-;;/m00../s1

InChI key

LGRFYKXKCZKDLS-DIYDTZFBSA-N

General description

Esomeprazole is the (S)-isomer of omeprazole. It blocks the H+/K+-ATPase enzyme and lowers the release of hydrochloric acid by gastric parietal cells. Esomeprazole is used for treating gastroesophageal reflux disease (GERD).

Application

Esomeprazole magnesium hydrate has been used to induce intracellular acidification in an ATP12A-independent manner.

Biochem/physiol Actions

Esomeprazole magnesium dihydrate is a leading proton pump inhibitor.

Features and Benefits

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Zákazníci si také prohlíželi

Slide 1 of 10

1 of 10

Lansoprazole ≥98% (TLC), powder

Sigma-Aldrich

L8533

Lansoprazole

Pantoprazole sodium hydrate ≥98% (HPLC)

Sigma-Aldrich

P0021

Pantoprazole sodium hydrate

Rabeprazole sodium ≥98% (HPLC)

Sigma-Aldrich

SML0476

Rabeprazole sodium

Omeprazole analytical standard

Supelco

19329

Omeprazole

Cariporide ≥98% (HPLC)

Sigma-Aldrich

SML1360

Cariporide

Bupivacaine hydrochloride monohydrate analytical standard, for drug analysis

Supelco

B5274

Bupivacaine hydrochloride monohydrate

Omeprazole Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1059

Omeprazole

Omeprazole United States Pharmacopeia (USP) Reference Standard

USP

1478505

Omeprazole

Acetazolamide ≥99%, powder

Sigma-Aldrich

A6011

Acetazolamide

Cannabigerol solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

C-141

Cannabigerol solution

A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD)
Kalaitzakis E and Bjornsson E
Therapeutics and Clinical Risk Management, 3(4), 653-653 (2007)
Yukiko Nakagawa et al.
Biological & pharmaceutical bulletin, 43(4), 682-687 (2020-04-03)
We previously showed that adhesive aggregates were formed when levofloxacin hydrate tablets and lansoprazole orally disintegrating (OD) tablets were suspended in water in the clinical context. In this study, we have clarified the factors causing aggregate formation, focusing on the
Esomeprazole
Scott LJ, et al.
Drugs, 62(10), 1503-1538 (2002)
Mark Rochman et al.
The Journal of allergy and clinical immunology, 147(5), 1924-1935 (2020-12-09)
Proton pump inhibitors (PPIs) have been recognized as a primary treatment of eosinophilic esophagitis (EoE), an allergic inflammatory disease of the esophageal mucosa. The mechanisms underlying esophageal epithelial responses to PPIs remain poorly understood. We hypothesized that PPIs can counteract
Esomeprazole increases airway surface liquid pH in primary Cystic Fibrosis epithelial cells
Delpiano L, et al.
Frontiers in Pharmacology, 9 (2018)
Zobrazit všechny související dokumenty

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.